Theravance keeps ampreloxetine alive after CYPRESS miss, but FDA demands another pivotal trial

The failed primary endpoint remains the central fact. CYPRESS did not achieve statistical significance on its week-8 OHSA primary endpoint, and the key secondary endpoint showed a similar late-period deterioration. 〔0〕 (Executive Summary for CYPRESS Study 0197) The miss was already public, along with the company’s decision to wind down the program, so this filing is not a fresh clinical success surprise.

The new information is that the program is not completely dead. Theravance’s focused, longitudinal post hoc analysis found statistically significant treatment differences across OHSA, OHDAS, and OHQ in a 47-patient subgroup, while blood-pressure, heart-rate, and norepinephrine changes preserved evidence of biological activity. (Average Treatment Effects; Plasma Norepinephrine Levels; Blood Pressure and Heart Rate Responses) 〔1〕 (Executive Summary for CYPRESS Study 0197)

The FDA signal is constructive but heavily qualified. The agency said the existing clinical package cannot support approval, but acknowledged that an additional pivotal trial leveraging prior data could create a potential path forward. 〔2〕 (FDA Interactions) That is better than a definitive regulatory dead end, but it replaces the hoped-for filing with another expensive, uncertain study.

Net: modestly better than the post-miss baseline, not a recovery of the original thesis. The market already knew the trial had failed and that ampreloxetine was being wound down; the incremental value here is regulatory optionality, not approval-ready evidence. The FDA’s willingness to discuss a future study is therefore a narrow positive, while the explicit rejection of the current package caps the read.